Intranasal neuropeptide Y was well tolerated in a 26-person PTSD trial

How is neuropeptide Y supposed to protect against PTSD?

Neuropeptide Y is hypothesized to act as a brake on stress reactivity in the brain's fear and stress circuits. In that model, depletion of the NPY system under chronic or severe stress leaves a person more vulnerable to anxiety and fear-related symptoms.

NPY is one of the most abundant peptides in the mammalian brain. It is released alongside norepinephrine in the circuits that govern the fear and stress response.

What does intranasal NPY do in rat models of PTSD?

In rats, a single intranasal NPY infusion prevented and reversed behavioral impairments in the single prolonged stress model, a model built to mimic PTSD, according to a 2026 review ^[7]. The rodent evidence behind the brake hypothesis is strong.

The rat data carry a notable wrinkle. Female rats needed higher doses, or pretreatment with a DPP-IV inhibitor, to get the same protective effect as males ^[7]. That sex difference alone is a clue that the human dosing picture is more complicated than a single fixed dose applied uniformly.

Has intranasal neuropeptide Y been tested in people with PTSD?

Intranasal neuropeptide Y has been tested in PTSD once, in a 2018 single-dose, randomized, double-blind, placebo-controlled, cross-over dose-escalation study of 26 people ^[2]. The participants were split across five dose cohorts from 1.4 mg to 9.6 mg, and 24 completed both treatment days ^[2].

The primary outcome was safety and tolerability, measured by adverse events, and the trial met it: NPY was well tolerated at every dose tested, including the highest ^[2].

The PTSD trial is one of only two small human trials of intranasal NPY; the other tested depression ^[1]. Each deserves to be read on its own terms rather than folded into the animal or correlational literature.

Did intranasal neuropeptide Y reduce PTSD symptoms?

In the 2018 PTSD trial, higher intranasal NPY doses were associated with a larger drop in anxiety than placebo, but only as a secondary outcome after a single dose ^[2]. Anxiety was measured with the Beck Anxiety Inventory and the State-Trait Anxiety Inventory after a trauma-script provocation, and the analysis showed a significant dose-by-treatment interaction ^[2].

The signal is real and statistically reported. It is also a single-dose, single-site, small-sample finding. No trial powered to detect a clinical response over time has followed it.

What did the intranasal NPY trial in depression find?

A 2020 randomized controlled trial in major depressive disorder found that a single 6.8 mg intranasal NPY dose improved mood at 24 hours, with no significant difference by 48 hours ^[1].

The trial enrolled 30 patients on stable antidepressant therapy, 12 on NPY and 18 on placebo ^[1]. MADRS scores dropped more in the NPY group at 24 hours (effect size d = 0.67, p = .04), with a similar trend at 5 hours that reached borderline significance ^[1].

The depression trial is tier-two evidence: controlled, but small, short, and in a different diagnosis than PTSD. It shows the same shape as the PTSD data, a same-day biological effect real enough to report and too brief and too small to call a treatment. Neither trial has a published successor, and no phase 2 PTSD efficacy trial powered on a clinical endpoint over weeks has been published.

Do soldiers with naturally high NPY prove the treatment works?

Higher natural NPY levels in soldiers under stress are a biomarker association, not evidence that giving NPY as a drug recreates that resilience. The claim circulates in resilience and nootropic content: soldiers or operators with naturally higher NPY handle acute stress better.

That claim correlates people's own endogenous NPY levels with performance under stress. A molecule that correlates with resilience is not the same as a molecule that recreates resilience when administered from outside.

Human stress-resilience research does treat plasma NPY as a biomarker of interest in high-stress training. A controlled study of mindfulness training in Marines preparing for deployment tracked plasma NPY as one of several physiological outcomes of the resilience intervention ^[4]. That is biomarker evidence, a different tier from an administration trial.

Why has intranasal NPY never reached a PTSD efficacy trial?

The best-supported explanation is an unresolved delivery problem compounded by weak commercial incentive, not evidence that intranasal NPY failed. Two explanations compete, and the literature supports one better than the other.

The "just needs funding" story implies NPY works and nobody paid to prove it. The more defensible reading is an unresolved pharmacology problem. NPY is a large peptide, and getting clinically meaningful concentrations across the nasal mucosa into the CNS is a real delivery challenge ^[7].

The 2026 review that reargues the preclinical and clinical case for intranasal NPY still holds that this challenge must be solved through formulation and dosing refinements rather than treated as settled ^[7]. No new human efficacy trial has been published ^[7].

Patent protection adds a second barrier. NPY is a natural peptide with limited patent protection, so the commercial case for an expensive, multi-year phase 2 trial gets thin regardless of the underlying biology.

How does intranasal NPY's record compare with other candidates?

Other intranasal peptide programs followed the same course: oxytocin dose-escalation studies in frontotemporal dementia and in Prader-Willi syndrome used small samples and made safety the primary endpoint ^[3]⁠^[5]. Both established tolerability, and both were followed by years-long gaps before, or without, any larger efficacy trial ^[3]⁠^[5].

That pattern is what an early-stage peptide program looks like, and it is not unique to NPY. Nasal oxytocin's broader trial record is covered separately.

Ketamine shows what advancing past that stage looks like. Ketamine, another candidate proposed for PTSD on the basis of a distinct rapid mechanism, has already been pooled across multiple randomized trials totaling over 800 participants, in a patient-level meta-analysis of ketamine infusion for depression ^[8]⁠^[6].

What is still unknown about intranasal neuropeptide Y?

Intranasal NPY's receptor targets, repeated-dose effects, sex differences, and brain delivery all remain unresolved in humans:

• Receptor subtype. The trials do not report which NPY receptor subtype, Y1, Y2, or Y5, does the work. Receptor pharmacology in this system is known to have region-dependent, sometimes opposing effects. No NPY trial has addressed that complexity, and it should not be assumed away.
• Repeated dosing. No trial shows whether repeated dosing would sustain the transient signal seen at 24 hours.
• Sex differences. Whether the sex-dependent dosing seen in rodents applies to humans is not established.
• Brain delivery. No trial establishes whether intranasal delivery reaches the brain at all at the concentrations tested. A separate explainer covers how nasal peptides reach the brain, and intranasal insulin faces its own delivery question.

Until a trial is designed to answer those questions directly, intranasal NPY for PTSD is tolerated, mechanistically plausible, and unproven.